RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX) major shareholder Spa Essetifin acquired 17,933,673 shares of the business’s stock in a transaction on Tuesday, March 13th. The shares were bought at an average cost of $0.23 per share, for a total transaction of $4,124,744.79. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX) traded up $0.01 during mid-day trading on Wednesday, reaching $0.23. 111,867 shares of the company’s stock were exchanged, compared to its average volume of 46,053. The company has a current ratio of 0.30, a quick ratio of 0.30 and a debt-to-equity ratio of -0.10. RegeneRx Biopharmaceuticals Inc has a 12 month low of $0.14 and a 12 month high of $0.38. The firm has a market capitalization of $25.25, a PE ratio of -23.00 and a beta of -1.97.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/03/14/spa-essetifin-acquires-17933673-shares-of-regenerx-biopharmaceuticals-inc-rgrx-stock.html.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.